VolitionRx Ltd. has announced that its Nu.Q NETs H3.1 assay has been selected as the exclusive biomarker for France's national sepsis detection evaluation program called DETECSEPS. This government-funded initiative, part of the France 2030 plan and supported by a €6.3 million grant, aims to revolutionize emergency care for patients with infections and sepsis risk. The program is led by the IHU SEPSIS research institute.
The significance of this selection lies in the potential to dramatically improve early sepsis identification in emergency settings. Professor Djillali Annane, Scientific Director of DETECSEPS, explained that combining Volition's biomarker with the established NEWS2 clinical score could enhance early detection capabilities. He noted that the H3.1 biomarker shows strong correlation with disease severity and provides superior prognostic utility for predicting outcomes including organ failure and mortality. According to Professor Annane, the biomarker's prognostic power at intensive care unit admission significantly exceeded established severity scores such as APACHE II and SOFA.
From a practical implementation perspective, Volition's Chief Medical Officer Dr. Andrew Retter emphasized that the biomarker can deliver results within one hour using the Immunodiagnostic Systems i10 automated analyzer. This rapid turnaround time could enhance emergency decision-making processes. The company believes that earlier sepsis identification could save lives, improve survivors' quality of life, and reduce burdens on healthcare systems.
The broader implications of this development extend beyond immediate clinical applications. Sepsis represents a significant global health challenge, with delayed detection contributing to poor outcomes and high mortality rates. The French government's investment in this evaluation program signals recognition of the need for improved diagnostic tools in emergency medicine. For more information about Volition's technology and research, visit https://www.Volition.com.
Volition is providing the Nu.Q H3.1 Assay pro-bono to support this important evaluation, demonstrating the company's commitment to advancing sepsis detection capabilities. The selection of a single biomarker for a national healthcare initiative represents a significant validation of Volition's epigenetic approach to disease detection. This development could potentially influence sepsis detection protocols beyond France if the evaluation demonstrates significant clinical benefits.
